Cognition Therapeutics, Inc. Stock Split Ratio
Cognition Therapeutics, Inc. (CGTX) reported Stock Split Ratio of 30.92% for the 1-month period ending 2021-07-31, per its 10-K filed 2023-03-23.
Discontinued › Notes › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2023-03-23
- 2021-07-31: Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month 30.92%; Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month as first filed 323.45%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month as first filed |
|---|---|---|
| 2021-07-31 | 30.92% 10-K · filed 2023-03-23 | 323.45% 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |